Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03897231|
Recruitment Status : Not yet recruiting
First Posted : April 1, 2019
Last Update Posted : April 1, 2019
Non-adherence to medication among patients on chronic hemodialysis compromises treatment effects and results in increased morbidity, mortality and extensive costs to the healthcare system. To our knowledge, no studies have investigated the prevalence of non-adherence among Danish hemodialysis patients using a validated measure of non-adherence.
The primary aim of this study was to investigate the prevalence of non-adherence among Danish patients on chronic hemodialysis measured by self-report.
Our second aim was to explore patients' beliefs about medicines and potential associations between beliefs and non-adherence to medication.
Our third aim was to explore the prevalence and severity of physical and emotional symptoms and potential associations with non-adherence to medication.
A multi-centre cross-sectional study according to the STROBE statement will be conducted from April 2019 - December 2020. The study will take place in the outpatient hemodialysis centres at three large University Hospitals in the Capital Region of Denmark.
|Condition or disease||Intervention/treatment|
|Medication Adherence End Stage Renal Failure on Dialysis||Other: questionnaire|
|Study Type :||Observational|
|Estimated Enrollment :||405 participants|
|Official Title:||Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis - a Multicenter Cross-sectional Study|
|Estimated Study Start Date :||April 1, 2019|
|Estimated Primary Completion Date :||December 1, 2019|
|Estimated Study Completion Date :||December 1, 2020|
- Other: questionnaire
Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (CPB) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
- the Morisky-Green-Levine scale (MAQ) [ Time Frame: up to 8 months ]number of participants with non-adherence to medication assessed by scores of ≥1 indicating non-adherence
- Medication adherence report scale (MARS) [ Time Frame: up to 8 months ]number of participants with non-adherence to medication assessed by scores of less than 25 points indicating non-adherence
- Beliefs about medicines (BMQ) [ Time Frame: up to 8 months ]number of participants that believe the necessity of their medication outweighs the cost of taking it assessed by scores ranging fra - 20 to + 20, with a postivie number indicating that patients belief in the benefit of mediciations overweights concerns about taking them
- Dialysis symptom index [ Time Frame: up to 8 months ]the overall symptom burden assessed by the total number of symptoms reported by each participant.
- Dialysis symptom index [ Time Frame: up to 8 months ]the overall symptom severity score assessed by scores ranging from 0-150 using a five-point Likert scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03897231
|Contact: Trine Mechta Nielsen, Phd Student||0045 firstname.lastname@example.org|
|Contact: Thordis Thomsen, Assprofessoremail@example.com|
|Principal Investigator:||Bo Feldt-rasmussen, Professor||Department of Nephrology, Rigshospitalet|